Navigation Links
Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
Date:1/9/2012

EAST SETAUKET, N.Y., Jan. 9, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings (OTC: LIXT.PK) announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

Dr. John S. Kovach, founder and president of Lixte, said, "We have developed a series of novel compounds primarily as potential treatments for several common cancers as well as brain tumors of adults and children.  Some of these compounds, however, have been shown in laboratory studies to affect the biochemical status of human brain cells in ways believed to be beneficial to normal cell function and, unlike most potent anti-cancer drugs, appear to have tolerable toxicity in animals even when given for many days. We are looking to develop these compounds as neuroprotective agents of potential relevance to the prevention and treatment of a broad spectrum of neurodegenerative diseases, including acute neurological injury and chronic conditions such as Alzheimer's disease and Parkinson's disease.  Because Lixte is predominantly focused on developing anti-cancer drugs, we are interested in exploring licensing and/or partnerships for development of our lead compounds with companies having major programs in prevention and treatment of neurological illnesses."

About Lixte Biotechnology Holdings, Inc.

Lixte is a cancer drug discovery company, using biomarker technology and innovative chemistry to develop new potentially more effective anti-cancer drugs. It has lead compounds in two classes of drugs, protein phosphatase inhibitors for which a US patent was recently issued with world-wide patent applications pending for its lead compound LB-100 and structural variants , and novel histone deacetylase inhibitors for which broad patent applications are also pending.
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
2. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
3. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
4. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
5. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
6. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
7. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
8. Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology
9. Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics
10. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape
11. Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)...  Novation, a VHA and UHC company, today ... features that automate key health care supply chain ... Association.  The new and enhanced ... Value Analysis, Item Master and Formulary – are ... most critical challenges brought on by health care ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5
... 2011 PediaVision today announced that Loma Linda ... the State of California to receive the revolutionary ... University,s Department of Ophthalmology is offering free vision ... the support of First 5 Riverside , ...
... small businesses struggle to afford health benefits, a ... Health Benefits regulations could include special interest protections that ... costs, the Pharmaceutical Care Management Association (PCMA) ... for thousands of small businesses throughout America. ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4Some Essential Benefits Rules Could Worry Small Businesses 2
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by Type ... & Others), by Application (Oil & Gas, Chemical, CSP, ... & Forecasts to 2019” defines and segments the global ... of the global consumption in terms of volume and ... spread through 199 page sand in-depth TOC on"Heat Transfer ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... mount in U.S. courts, Bernstein Liebhard LLP notes that ... medications in men with Type 2 diabetes. The research, ... Endocrinology & Metabolism on June 30th, involved 88 men ... had mild to moderate aging male symptoms and erectile ...
(Date:7/29/2014)... negotiations may depend on more than diplomacy. When it comes ... according to a new study. Researchers found ... for themselves than men with narrower faces. However, having ... require collaboration and compromise, the researchers found. "We negotiate ... not just the big things, like a car or a ...
(Date:7/29/2014)... Society of America (GSA) and the National Center ... PhD, of Columbia University as the 2014 recipient of ... Aging. , This award recognizes and honors the seminal ... field of creativity and aging shifted the conceptual focus ... potential. Cohen inspired individuals to approach longevity asking what ...
(Date:7/29/2014)... in boys with fragile X syndrome tend to ... study of the inherited disorder to date has ... everyday social and practical skills, including communication, socialization, ... getting dressed. In this study, socialization emerged as ... in that it did not decline as much ...
Breaking Medicine News(10 mins):Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Wider Face May Give You an Edge in Negotiations 2Health News:Charon to receive 2014 Gene D. Cohen Award 2Health News:Socialization relative strength in fragile X longitudinal study 2
... , THURSDAY, Jan. 27 (HealthDay News) -- Most ... at home, and quickly learn which types of brand-name fast ... In one experiment, the mothers of 67 children, aged 3 ... and listed foods high in sugar, fat and salt. The ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Modern ... research suggests. An ancient human toolkit with hand axes, ... east Africa -- but not the Middle East -- was ... that the toolkit dates back 100,000 to 125,000 years, researchers ...
... Washington, DC, January 27, 2011 Screening patients in ... (MRSA) produces cost savings for the whole hospital, according ... published in the February issue of the American ... APIC - the Association for Professionals in Infection Control ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Work-related ... has found. Israeli researchers gave hearing tests to 298 ... harmful noise and found that 99 of the workers had ... hearing problems tended to be older and to have been ...
... BEER SHEVA, ISRAEL January 27, 2011 -- A ... researchers indicates that physicians who give second opinions may ... factors. In the study, the researchers presented ... a national sample of orthopedic surgeons and neurologists. Some ...
... (RA) patients who failed to respond to methotrexate were ... an oral spleen tyrosine kinase (Syk) inhibitor that is ... and cartilage destruction. In the current study, RA patients ... In contrast to the prior study, however, fostamatinib was ...
Cached Medicine News:Health News:Kids Fed Unhealthy Foods Learn to Prefer Them 2Health News:Ancient Toolkit Holds Clues to Migration of Early Man 2Health News:Study finds MRSA screening saves hospitals money 2Health News:Ben-Gurion U. researchers determine that a first medical opinion can influence the second 2Health News:Fostamatinib proven to be safe but not effective 2
... ENDOPATH EZ45 Endoscopic Linear Cutter has application ... surgical procedures for transection, resection, and/or creation ... staple line or tissue buttressing materials such ... reloaded seven times for a total of ...
... Linear Cutters provide a 45mm staple and ... the device suitable for many minimally invasive ... transection, resection, and/or creation of anastomoses in ... ,The LONG45A Endocutter has a shaft ...
ACUCLIP Endoscopic Right-Angle Multiple Clip Applier, 10 mm Shaft Diameter with 20, 8 mm Titanium Clips...
Insert only, Pilling-Weck medium clip size...
Medicine Products: